{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:44:07Z","timestamp":1790775847969,"version":"4.1.0"},"reference-count":28,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T00:00:00Z","timestamp":1620864000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Despite a solid rationale, the usefulness of antioxidants in treating vitiligo has not been clearly demonstrated. Combining superoxide dismutase (SOD) with a wheat gliadin biopolymer protects it during the passage through the gastrointestinal tract.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To evaluate the efficacy of gliadin\u2010protected SOD (GP\u2010SOD), associated with narrowband ultraviolet B(NB\u2010UVB), for treating vitiligo.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a 24\u2010week monocentric interventional prospective randomized placebo\u2010controlled trial in the tertiary center for vitiligo care in the department of Dermatology of Nice University hospital, Nice, France.<\/jats:p><jats:p>Subjects with non\u2010segmental vitiligo affecting more than 5% of the total body surface were included. The subjects received gliadin\u2010protected SOD (GP\u2010SOD; 1\u00a0g\/day for 12\u00a0weeks followed by 0.5\u00a0g\/day for 12\u00a0weeks) or placebo in combination with twice\u2010weekly sessions of NB\u2010UVB. The primary endpoint was the total repigmentation rate at 24\u00a0weeks, compared with baseline, as assessed by investigator\u2010assessed Vitiligo Extent Score (VES) on standardized pictures.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 50 patients were included. After 24\u00a0weeks, a greater improvement in VES was observed in the GP\u2010SOD group (19.85%; SE 4.63,<jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.0001) compared with the placebo group (8.83%; SE 4.72,<jats:italic>P<\/jats:italic>\u00a0=\u00a00.0676). Tolerance was good in both groups. No related side\u2010effect was reported.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The use of GP\u2010SOD appears to be a useful add\u2010on to phototherapy in the treatment of vitiligo patients.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jdv.17331","type":"journal-article","created":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T01:42:20Z","timestamp":1619833340000},"page":"1725-1729","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Oral gliadin\u2010protected superoxide dismutase in addition to phototherapy for treating non\u2010segmental vitiligo: A 24\u2010week prospective randomized placebo\u2010controlled study"],"prefix":"10.1111","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1849-9626","authenticated-orcid":false,"given":"E.","family":"Fontas","sequence":"first","affiliation":[{"name":"CHU Nice Department of Clinical Research and Innovation Universit\u00e9 C\u00f4te d\u2019Azur Nice France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0528-4829","authenticated-orcid":false,"given":"H.","family":"Montaudi\u00e9","sequence":"additional","affiliation":[{"name":"CHU Nice Department of Dermatology Universit\u00e9 C\u00f4te d\u2019Azur Nice France"},{"name":"INSERM U1065 C3M Universit\u00e9 C\u00f4te d\u2019Azur Nice France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0797-6570","authenticated-orcid":false,"given":"T.","family":"Passeron","sequence":"additional","affiliation":[{"name":"CHU Nice Department of Dermatology Universit\u00e9 C\u00f4te d\u2019Azur Nice France"},{"name":"INSERM U1065 C3M Universit\u00e9 C\u00f4te d\u2019Azur Nice France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,5,13]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2016.11.002"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16072"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.07.011"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3680"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2012.328"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.22027"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1096\/fj.12-226779"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jidsp.5640189"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09963-8"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2015.335"},{"key":"e_1_2_6_12_1","first-page":"598","article-title":"Free radicals, antioxidants, and human disease: where are we now?","volume":"119","author":"Halliwell B","year":"1992","journal-title":"J Lab Clin Med"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2005.12.087"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-013-1113-5"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/ced.12950"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.13499"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.52.2.218"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/ptr.1542"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-006-0518-6"},{"key":"e_1_2_6_20_1","first-page":"254","article-title":"Could a photobiological test be a suitable method to assess the anti\u2010oxidant effect of a nutritional supplement Glisodin?","volume":"17","author":"Mac\u2010Mary S","year":"2007","journal-title":"Eur J Dermatol"},{"key":"e_1_2_6_21_1","first-page":"45","article-title":"GliSODin, a vegetal sod with gliadin, as preventative agent vs. atherosclerosis, as confirmed with carotid ultrasound\u2010B imaging","volume":"39","author":"Cloarec M","year":"2007","journal-title":"Eur Ann Allergy Clin Immunol"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.12.041"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2015.12.040"},{"key":"e_1_2_6_24_1","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1111\/pcmr.12784","article-title":"Validation of a physician global assessment tool for vitiligo extent: results of an international vitiligo expert meeting","volume":"32","author":"Geel N","year":"2019","journal-title":"Pigment Cell Melanoma Res"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.1994.tb01167.x"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2019.11.031"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14792"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2017.0002"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30609-7"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.17331","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jdv.17331","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.17331","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T04:16:38Z","timestamp":1698984998000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.17331"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,13]]},"references-count":28,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["10.1111\/jdv.17331"],"URL":"https:\/\/doi.org\/10.1111\/jdv.17331","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,13]]},"assertion":[{"value":"2021-02-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-13","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}